Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Stavros Stavrakis"'
Publikováno v:
Am J Cardiol
Obesity is common in heart failure with preserved ejection fraction (HFpEF). Whether obesity modifies the response to spironolactone in patients with HFpEF remains unclear. We aimed to investigate the effect of obesity, defined by body mass index (BM
Autor:
Mulan Tang, Stavros Stavrakis, Khaled Elkholey, Jeremy Houser, Lynsie Morris, Monika Niewiadomska, Michelle Ramirez, Mary Beth Humphrey
Publikováno v:
Exp Physiol
New findings What is the central question of this study? Prior studies failed to address the role of sex in modifying the pathophysiology and response to therapy in heart failure with preserved ejection fraction (HFpEF), potentially introducing bias
Autor:
Monika Niewiadomska, Lynsie Morris, Samantha Stansbury, Lyndee Branen, Avery Melton, Angela Herron, Raisa Monteiro, Khaled Elkholey, Mahesh Kumar Sivasubramanian, Priya Balasubramanian, Stavros Stavrakis, Madhan Subramanian, Laura Edwards
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Scientific Reports
The anti-inflammatory effects of vagus nerve stimulation are well known. It has recently been shown that low-level, transcutaneous stimulation of vagus nerve at the tragus (LLTS) reduces cardiac inflammation in a rat model of heart failure with prese
Autor:
Gary Tse, George Bazoukis, Jagmeet P. Singh, Jiandong Zhou, Qingpeng Zhang, Sandeep Chandra Bollepalli, Stavros Stavrakis, Antonis A. Armoundas
Publikováno v:
Heart Failure Reviews
Machine learning (ML) algorithms “learn” information directly from data, and their performance improves proportionally with the number of high-quality samples. The aim of our systematic review is to present the state of the art regarding the impl
Autor:
Sunny S. Po, Stavros Stavrakis, Benjamin J. Scherlag, Zain Ul Abideen Asad, Khaled Elkholey, Nicole T. Tran
Publikováno v:
J Cardiovasc Transl Res
Low-level transcutaneous vagus nerve stimulation at the tragus (LLTS) is anti-adrenergic. We aimed to evaluate the acute effects of LLTS on left ventricular (LV) function and autonomic tone. Patients with diastolic dysfunction and preserved LV ejecti
Autor:
David R. Van Wagoner, Lynsie Morris, Stavros Stavrakis, Olujimi A. Ajijola, Ayahiro D Takashima, Khaled Elkholey
Publikováno v:
JACC Clin Electrophysiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07f5d03b10798cde0a491038d693e50a
https://europepmc.org/articles/PMC8450521/
https://europepmc.org/articles/PMC8450521/
Autor:
Gabor A. Fulop, Andriy Yabluchanskiy, Sarah E Johnston, Stavros Stavrakis, Rajesh Samannan, Sunny S. Po, Agnes Lipecz, Tamas Csipo, Faris Amil, Yunqiu Jiang, Federico Silva-Palacios, Yan D. Zhao, Tarun W. Dasari
Publikováno v:
J Card Fail
Background Autonomic dysregulation in heart failure with reduced ejection fraction plays a major role in endothelial dysfunction. Low-level tragus stimulation (LLTS) is a novel, noninvasive method of autonomic modulation. Methods and Results We enrol
Autor:
Stavros, Stavrakis, Kanchan, Kulkarni, Jagmeet P, Singh, Demosthenes G, Katritsis, Antonis A, Armoundas
Publikováno v:
JACC Clin Electrophysiol
The autonomic nervous system plays a central role in the pathogenesis of multiple cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia. As such, autonomic modulation represents an attractive therapeutic approach in these con
Autor:
Warren M. Jackman, Stavros Stavrakis, Ralph Lazzara, Benjamin J. Scherlag, Hiroshi Nakagawa, Sunny S. Po
Publikováno v:
JACC: Clinical Electrophysiology. 1:1-13
Recent experimental and clinical studies have shown that the epicardial autonomic ganglia play an important role in the initiation and maintenance of atrial fibrillation (AF). In this review, we present the current data on the role of the autonomic g
Autor:
Stavros Stavrakis, Julie A. Stoner, Sunny S. Po, Ralph Lazzara, Joel Kardokus, Paul Garabelli
We hypothesized that intermittent anticoagulation based on daily rhythm monitoring using the novel oral anticoagulants (NOACs) is feasible and safe among patients with paroxysmal atrial fibrillation (AF). Patients with paroxysmal AF and ≥1 risk fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ce9a58f86658b1a57015dcde343ab43
https://europepmc.org/articles/PMC5458416/
https://europepmc.org/articles/PMC5458416/